同步放化疗联合恩度治疗局部中晚期非小细胞肺癌的疗效

Therapeutic Efficacy of Concurrent Radiotherapy and Chemotherapy Combined with Endostar on Locally Advanced Non-small Cell Lung Cancer

目的 :探讨同步放化疗联合恩度治疗局部中晚期非小细胞肺癌的临床疗效,并观察其对患者生存质量的影响,为临床局部中晚期非小细胞肺癌患者规范、高效的治疗提供有力依据。方法 :按随机数字表法将78例局部中晚期非小细胞肺癌(腺癌)患者分为对照组(培美曲塞500 mg/m2,静脉注射15 min,每3周重复1次;同步行放疗)与治疗组(在对照组基础上加恩度15 mg+500 m L 0.9%氯化钠注射液,静脉滴注,连续应用14 d,每3周重复1次),各39例。统计分析两组12个月生存率、中位进展时间及中位生存期;评价两组临床疗效,采用卡氏功能状态评分标准(KPS)评价两组患者治疗前、后生存质量,并记录治疗期间不良反应。结果:治疗组1年生存率为92.31%,明显高于对照组的71.79%(P<0.05);中位进展时间、中位生存期明显高于对照组(P<0.05)。治疗组总有效率为76.92%,明显高于对照组的48.72%(P<0.05);治疗组与对照组治疗后KPS评分明显高于治疗前,且治疗组KPS评分明显高于对照组(P<0.05)。治疗组不良反应发生率为43.59%,与对照组的48.72%比较无统计学差异(P>0.05)。结论:同步放化疗辅以恩度治疗中晚期非小细胞肺癌可提高临床疗效及患者生存期,改善其生存质量,且不会增加不良反应,值得推广。

Objective:To investigate the clinical efficacy of concurrent radiochemotherapy combined with endostar on locally advanced non-small cell lung cancer(NSCLC) and to observe the effect on the quality of life of the patients, thus providing a powerful basis for standardized and effective treatment of patients with locally advanced non-small cell lung cancer. Methods:78 patients with locally advanced non-small cell lung cancer(adenocarcinoma) were randomly divided into control group(500 mg/m2 pemetrexed, intravenous infusion for 15 min, once every 3 weeks, together with synchronous radiation therapy) and treatment group(15 mg endostar formulated in 500 m L 0.9% sodium chloride, intravenous drip infusion for continuous 14 days, once every 3 weeks, in addition to the treatment in control group), with 39 cases in each group. The 12-month survival rate, median time to progression and median survival time of the two groups were analyzed, the clinical curative effect of the two groups was evaluated, the life quality of the two groups before and after treatment was evaluated by Karnofsky Performance Status(KPS). And the adverse reactions during the treatment were recorded. Results:The 1-year survival rate of the treatment group is 92.31%, significantly higher than that in the control group with 71.79%(P<0.05). The median time to progression and median survival time of the treatment group are significantly higher than those in the control group(P<0.05). The total effective rate is 76.92% in the treatment group, which is obviously higher than 48.72% in the control group(P<0.05). The KPS scores of the treatment group and the control group are apparently increased after the treatment when compared with those before the treatment, with KPS score of the treatment group significantly higher than that of the control group(P<0.05). The adverse reaction rates in the treatment group and control group are 43.59% and 48.72%, respectively, without significant statistical difference(P>0.05). Conclusion:Concurrent radiotherapy and chemotherapy combined with endostar would increase clinical effect and median survival time, and improve the quality of life of patients with locally advanced non-small cell lung cancer(NSCLC), without increased adverse reactions, it is worth popularization.